Kentucky Retirement Systems Has $12.63 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Kentucky Retirement Systems reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,424 shares of the medical research company’s stock after selling 205 shares during the period. Kentucky Retirement Systems’ holdings in Amgen were worth $12,630,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Marathon Trading Investment Management LLC bought a new position in Amgen in the second quarter valued at $469,000. Seven Eight Capital LP acquired a new stake in shares of Amgen in the second quarter valued at about $845,000. Lokken Investment Group LLC boosted its position in Amgen by 13.6% during the second quarter. Lokken Investment Group LLC now owns 3,742 shares of the medical research company’s stock valued at $1,169,000 after purchasing an additional 449 shares during the last quarter. Waterloo Capital L.P. bought a new stake in shares of Amgen during the 2nd quarter worth approximately $231,000. Finally, Blair William & Co. IL increased its holdings in Amgen by 38.3% during the second quarter. Blair William & Co. IL now owns 187,658 shares of the medical research company’s stock worth $58,634,000 after buying an additional 51,957 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.0 %

Shares of NASDAQ:AMGN opened at $332.92 on Thursday. The business’s 50 day simple moving average is $329.22 and its 200 day simple moving average is $305.00. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The company has a market capitalization of $178.59 billion, a P/E ratio of 47.56, a P/E/G ratio of 2.93 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the company posted $5.00 earnings per share. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.70%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMGN. TD Cowen upped their target price on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Bank of America boosted their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Morgan Stanley cut their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. Finally, Oppenheimer reissued an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. Eleven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.